Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272543 | 0.80 | MEN1 (0.47) | MEN1KMT2ASIGMAR1CYP2D6CYP3A4 | |
| SCHEMBL2931788 | 0.78 | MEN1 (0.46) | MEN1KMT2ASIGMAR1CYP2D6CYP3A4 | |
| SCHEMBL9301631 | 0.77 | MEN1 (0.45) | MEN1KMT2ASIGMAR1CYP2D6CYP3A4 | |
| SCHEMBL5592149 | 0.77 | OPRL1 (0.46) | MEN1KMT2ASIGMAR1CYP2D6CYP3A4 | |
| SCHEMBL8936204 | 0.77 | OPRL1 (0.46) | MEN1KMT2ASIGMAR1CYP2D6CYP3A4 | |
| SCHEMBL24696382 | 0.75 | OPRL1 (0.45) | MEN1KMT2ASIGMAR1CYP2D6CYP3A4 | |
| SCHEMBL24653982 | 0.75 | SIGMAR1 (0.41) | MEN1KMT2ASIGMAR1CYP3A4HSD17B10 | |
| SCHEMBL26619967 | 0.75 | SIGMAR1 (0.44) | MEN1KMT2ASIGMAR1CYP3A4HSD17B10 | |
| SCHEMBL24316045 | 0.74 | MEN1 (0.43) | MEN1KMT2ASIGMAR1CYP2D6CYP3A4 | |
| SCHEMBL25000121 | 0.74 | CYP2D6 (0.43) | MEN1KMT2ASIGMAR1CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | MEN1 4812/4885KMT2A 3866/4885SIGMAR1 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.